Grants and Contributions:

Title:

Phase 3 project for EB05(anti-TLR4 monoclonal antibody) in Hospitalized COVID-19 Patients

Agreement Number:

514239

Agreement Value:

$23,000,000.00

Agreement Date:

Oct 12, 2023 - Dec 31, 2045

Description:

This project will focus on the activities required for Phase 3 clinical trials/regulatory approval for their novel antibody treatment (EB05) targeting acute respiratory distress syndrome (ARDS), the most common cause of death in COVID-19 patients.

Organization:

Innovation, Science and Economic Development Canada

Expected Results:

This investment will advance Phase III clinical trials for an antibody therapy (EB05), for the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients. ARDS is a severe form of respiratory failure with a high mortality rate and few treatments available.

Location:

Markham, Ontario, CA L3R5H6

Reference Number:

033-2023-2024-Q3-514239

Agreement Type:

Other transfer payment

Report Type:

Grants and Contributions

Recipient Business Number:

815678123

Recipient Type:

For-profit organization

Additional Information:

This is a partially repayable contribution.

Recipient's Operating Name:

Edesa Biotech Research, Inc.

Recipient's Legal Name:

Edesa Biotech Research, Inc.

Federal Riding Name:

Markham--Unionville

Federal Riding Number:

35056

Program:

SIF Stream 1- R&D

Program Purpose:

-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.

NAICS Code:

339900